These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23677103)

  • 1. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 3. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
    Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
    Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
    [No Abstract]   [Full Text] [Related]  

  • 4. Sunitinib-induced subungual splinter haemorrhage and acral erythema.
    Nakamura M; Miyachi Y
    Eur J Dermatol; 2008; 18(3):344-5. PubMed ID: 18474471
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib-induced eruptive melanocytic lesions.
    Kong HH; Sibaud V; Chanco Turner ML; Fojo T; Hornyak TJ; Chevreau C
    Arch Dermatol; 2008 Jun; 144(6):820-2. PubMed ID: 18559790
    [No Abstract]   [Full Text] [Related]  

  • 6. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 7. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
    Al Enazi MM; Kadry R; Mitwali H
    J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute cardiac failure after sunitinib.
    Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
    Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
    Yıldız I; Varol U; Şen F; Kılıç L
    Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eruptive nevi associated with medications (ENAMs).
    Perry BM; Nguyen A; Desmond BL; Blattner CM; Thomas RS; Young RJ
    J Am Acad Dermatol; 2016 Nov; 75(5):1045-1052. PubMed ID: 27241804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.
    Tsai KY; Yang CH; Kuo TT; Hong HS; Chang JW
    J Clin Oncol; 2006 Dec; 24(36):5786-8. PubMed ID: 17179114
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to 'Thyrotoxicosis during sunitinib treatment for renal cell carcinoma' by Grossmann et al.
    Daniels GH
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):455. PubMed ID: 19138312
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Garfield DH; Hercbergs A; Davis PJ
    J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 17. Sunitinib-aggravated hypertension.
    Rivera F; Benounna M; Sánchez de la Nieta MD
    J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
    [No Abstract]   [Full Text] [Related]  

  • 18. [Sunitinib-induced pyoderma gangrenosum].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyoderma gangrenosum with the use of sunitinib.
    Nadauld LD; Miller MB; Srinivas S
    J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.